Caladrius Biosciences to Host First Quarter 2020 Financial Results Conference Call on Thursday, May 7, 2020
April 30 2020 - 8:30AM
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the
“Company”), a clinical-stage biopharmaceutical company dedicated to
the development of cellular therapies designed to reverse, not
manage, disease, today announced that it will report financial
results for the three months ended March 31, 2020 after the close
of the U.S. financial markets on Thursday, May 7, 2020.
Caladrius management will host a conference call for investors
beginning at 4:30 p.m. (ET) on Thursday, May 7, 2020 to discuss the
financial results and provide a business update.
Shareholders and other interested parties may participate in the
conference call by dialing 866-595-8403 (domestic) or 706-758-9979
(international) and referencing conference ID number 8869677. The
conference call will also be webcast live under the Investors
section of the Company's website at www.caladrius.com.
For those unable to participate in the live conference call, a
replay will be accessible approximately two hours after its
completion through May 14, 2020 by dialing 855-859-2056 (domestic)
or 404-537-3406 (international) and referencing conference ID
number 8869677. A webcast of the call will also be archived for 90
days under the Investors section of the Company’s website at
www.caladrius.com.
About Caladrius Biosciences
Caladrius Biosciences, Inc. is a clinical-stage
biopharmaceutical company dedicated to the development of cellular
therapies designed to reverse, not manage, cardiovascular disease.
We are developing a first- in-class cell therapy product that is
based on the notion that our body contains finely tuned mechanisms
for self-repair. Our technology leverages and enables these
mechanisms in the form of specific cells, using formulations and
modes of delivery unique to each medical indication.
The Company's current product candidates include three
developmental treatments for ischemic diseases based on its CD34+
cell therapy platform: CLBS12, recipient of SAKIGAKE designation
and eligible for early conditional approval in Japan for the
treatment of critical limb ischemia ("CLI") based on the results of
an ongoing clinical trial; CLBS16, the subject of a recently
completed positive Phase 2 clinical trial in the U.S. for the
treatment of coronary microvascular dysfunction ("CMD"); CLBS14, a
Regenerative Medicine Advanced Therapy ("RMAT") designated therapy
for which the Company has finalized with the U.S. Food and Drug
Administration (the "FDA") a protocol for a Phase 3 confirmatory
trial in subjects with no-option refractory disabling angina
("NORDA"); and CLBS119, a CD34+ cell therapy product candidate for
the repair of lung damage found in patients with severe COVID-19
infection who experienced respiratory failure, for which the
Company plans to initiate a clinical trial in the coming months.
For more information on the company, please
visit www.caladrius.com.
Contact:
Investors: Caladrius Biosciences, Inc. John Menditto Vice
President, Investor Relations and Corporate Communications Phone:
+1-908-842-0084 Email: jmenditto@caladrius.com
Media: W2O Group Christiana Pascale Phone: +1-212-257-6722
Email: cpascale@w2ogroup.com
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Apr 2023 to Apr 2024